Muhamed Baljevic, MD, FACP

Panelists discuss evolving approaches to maintenance therapy in newly diagnosed multiple myeloma, focusing on balancing survival benefits with tolerability. They also review the latest data from the AURIGA trial evaluating daratumumab and lenalidomide maintenance.

Panelists discuss the factors influencing the choice between isatuximab and daratumumab for induction therapy in transplant-eligible newly diagnosed multiple myeloma, as well as the role of dara-based quadruplet regimens as the standard of care and considerations for triplet regimens in specific patient populations.

Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.

Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.

Present initial results from the Phase 1 RedirecTT-1 trial exploring the combination of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

A summary of key discussion points and an overview of the evidence presented to inform the dialogue.